OH-PROAMPAC
ProAmpac, a leader in flexible packaging and material science, will showcase its products at Interpack, a worldwide exhibition for the packaging industry, in Hall 10, Stand D21. The event is scheduled to take place in Dusseldorf, Germany, from 4-10 May.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230501005442/en/
ProActive Recyclable R-2050 is a high-performance mono PE recyclable film that features superior heat resistance, excellent directional tear for easy opening and various barrier properties available to suit even the most sensitive products. (Photo: Business Wire)
"We're thrilled to be back at Interpack this year with sustainable packaging innovation and our expanded capabilities in Europe, Ireland, and the UK. Our recent additions, such as digital printing, spouted and aseptic pouching, and our commitment to ESG goals, enable us to collaborate on the latest innovations in flexible packaging," states Adam Grose, chief commercial officer for ProAmpac.
Sustainable Packaging Innovations
ProAmpac will showcase its sustainable offerings with its ProActive Sustainability® line of packaging. New product innovations on display include:
- ProActive Recyclable R-2050. This high-performance mono PE recyclable film features superior heat resistance, excellent directional tear for easy opening and various barrier properties available to suit even the most sensitive products.
- QUADLFEX Recyclable is a film-based quad packaging solution that is perfect for high-speed filling lines. This packaging can be customized with clear windows and surface finishes and is preapproved for recycling through the in-store drop-off program.
- ProActive Recyclable RP-1000, a recyclable paper-based product that provides barrier protection for dry and non-greasy food products.
- PRO-EVO Recyclable provides excellent grease and edge-wicking resistance without intentionally adding per- and poly-fluoroalkyl substances (PFAS). PRO-EVO Recyclable is also available with a high moisture barrier to maintain the freshness of pet foods.
- RAP Packaging Products keeps food to-go fresh and offers an elevated appearance in either a hot cabinet or a chiller. Also, by weight, the largest packaging component is paperboard and paper sourced from well-managed forests, which is widely recyclable in fibre streams. ProAmpac’s food to-go packaging solutions are 2023 OPRL 90/10 compliant.
- ProActive PIR film contains 30% polyethylene-based postindustrial recycled content, meets UK Plastic Packaging Tax guidelines for tax exemption and is OPRL compliant for front-of-store drop-off. All virgin material and film used to produce ProActive PIR film are EU food contact grade materials, which comply with Regulation (EU) No 10/2011 and have also undergone additional NIAS testing.
Thought Leadership
On Monday, 8 May, at 11:00 am, Sal Pellingra, the vice president of global package design, applications, and business development at ProAmpac, will be presenting ProAmpac's Approach to Sustainability at the Interpack TV Stage, situated between Halls 7 and 9 at the North Entrance. During the presentation, Sal will highlight sustainable market trends and ProAmpac’s collaborative approach to commercialization of new ProActive Sustainability® technologies toward a more circular economy.
To set up a meeting during the show or learn how ProAmpac’s team can help you, please contact Events@ProAmpac.com or visit ProAmpac.com.
About ProAmpac
ProAmpac is a leading global flexible packaging company with a comprehensive product offering, providing creative packaging solutions, industry-leading customer service and award-winning innovation to a diverse global marketplace. ProAmpac’s approach to sustainability – ProActive Sustainability® – provides innovative sustainable flexible packaging products to help our customers achieve their sustainability goals. We are guided in our work by five core values that are the basis for our success: Integrity, Intensity, Innovation, Involvement and Impact. Cincinnati-based ProAmpac is owned by Pritzker Private Capital along with management and co-investors. For more information, visit ProAmpac.com or contact Media@ProAmpac.com.
About Pritzker Private Capital
Pritzker Private Capital partners with middle-market companies based in North America with leading positions in the manufactured products and services sectors. The firm's differentiated, long duration capital base allows for efficient decision-making, broad flexibility with transaction structure and investment horizon, and alignment with all stakeholders. Pritzker Private Capital builds businesses for the long term and is an ideal partner for entrepreneur- and family-owned companies. Pritzker Private Capital is a signatory to the United Nations Principles for Responsible Investment (PRI). For more information, visit PPCPartners.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230501005442/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aesyra Demonstrates Significant Sleep Bruxism Reduction in Clinical Study26.1.2026 09:00:00 CET | Press release
Aesyra SA, a Swiss medtech company developing innovative digital therapeutics for dental and sleep-related disorders, today announced the successful completion of its clinical investigation evaluating the efficacy and safety of AesyBite™ Active, an intelligent oral appliance designed to treat and prevent sleep bruxism through biofeedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126533019/en/ AesyBite Custom smart nightguard by Aesyra SA. The clinical investigation demonstrated that AesyBite™ Active achieved a statistically significant and clinically meaningful reduction in sleep bruxism activity, exceeding the predefined performance target. Strong and robust clinical outcomes In the study (Identifier: NCT06153810), involving 26 adult patients with confirmed sleep bruxism, activation of the AesyBite Active biofeedback system resulted in a 60.6% reduction in total sleep bruxism duration per hour compared to baseline
Franklin Templeton Aligns Alternative Credit Firms Under BSP Brand26.1.2026 08:58:00 CET | Press release
Benefit Street Partners and Alcentra align under a single, refreshed BSP brand.Move reflects client demand for a specialist, integrated and global credit platform.Franklin Templeton’s alternative credit platform on track to exceed $100bn in 2026.BSP outlines further growth plans including expansion in the Middle East and Asia.New research says 51% of institutional investors will increase credit allocation in 2026.81% of institutions say a specialist focus on credit is the top attribute for performance. Franklin Templeton’s US and European alternative credit businesses, Benefit Street Partners and Alcentra, have now aligned under an updated Benefit Street Partners (BSP) brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123270080/en/ David Manlowe, CEO of Benefit Street Partners The move is the final step in BSP and Alcentra’s integration – two pioneering alternative credit firms that Franklin Templeton acquired in 2019
Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results26.1.2026 08:00:00 CET | Press release
In its first financial results announcement after the spin-off, Samsung Bioepis recorded FY2025 revenue of KRW 1.672 trillion, highest annual revenue in its 14-year historyExcluding milestone revenue, annual sales revenue grew 28% year-over-year (YoY), recording KRW 1.626 trillion, with 101% YoY growth in operating profit to KRW 330.8 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced financial results for the fourth quarter and fiscal year 2025. “We are very pleased to report strong year-to-date sales growth in our first financial results following the spin-off. Our organic growth has been driven by solid performance across our biosimilars portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are continuing to make meaningful progress in our regulatory and commercial milestones with our existing biosimilars portfolio, while strategically
Syngenta and Statkraft Sign Five-Year Virtual Power Purchase Agreement26.1.2026 08:00:00 CET | Press release
Virtual wind PPA with guarantees of origin to decarbonize Syngenta's plants in Europe Important element in carbon reduction journey for Syngenta AG Syngenta, one of the world’s biggest agricultural innovation companies, and Statkraft, a leading provider of innovative green energy solutions in Europe, have signed a virtual power purchase agreement (vPPA) covering Syngenta’s CP & Seeds operations for a period of five years. The volume amounts to 125 GWh per year and a total of 625 GWh of green electricity by the end of the contract in 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260125701845/en/ Syngenta and Statkraft sign five-year virtual power purchase agreement With the vPPA, Statkraft is supporting Syngenta in advancing its sustainability strategy through the purchase of renewable energy. "This is Syngenta's first vPPA, marking a pivotal step in our decarbonization strategy," said Rachel Stenson Bugnon, Global Hea
Merz Therapeutics Submits Application to the European Medicines Agency for New Indication of XEOMIN® in Pediatric Spasticity26.1.2026 08:00:00 CET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has completed the regulatory submission for XEOMIN® (incobotulinumtoxinA) for the treatment of spasticity of the lower and upper limb in children and adolescents aged 2–17 years in the European Union (EU) and European Economic Area (EEA). If approved, the indication would expand access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often debilitating condition in children and adolescents with certain neurological conditions, leading to increased muscle tone that can significantly limit movement, function and independence. One of the most common underlying causes of spasticity in children is cerebral palsy (CP), the most frequent motor disability in childhood, with spastic forms accounting for approximately 80% of all cases. In more severe cases, spasticity associated with CP can also affect spe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom